Regarding safety, cemiplimab’s adverse event (AE) profile was manageable and consistent with those established among PD-1 ...
At the molecular level, transcriptomic profiling of a single nucleus RNA-seq dataset of renal epithelial cells revealed ...
A recent clinical trial found that transplantation in lower-risk myelodysplastic syndrome (MDS) patients with high-risk ...
The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...
The FDA designates ofirnoflast as an orphan drug, highlighting its innovative approach to treating myelodysplastic syndromes ...
To understand treatment patterns and preferences, a series of expert-led Case-Based Roundtable events were conducted over the ...
The US FDA has approved the supplemental new drug application (sNDA) for revumenib (Revuforj) in the treatment of relapsed or ...
Dr Vishal A. Patel discusses the breakthrough in treating high-risk cutaneous squamous cell carcinoma with FDA-approved ...
1. Malandrakis, P. Sustained marrow and imaging MRD negativity can lead to lenalidomide discontinuation following ASCT in multiple myeloma: Updated results from a prospective cohort study. Presented ...
A panelist discusses how patient comorbidities and declining performance status drive individualized treatment planning in ...
Targeted Therapies in Oncology | Targeted Publications | Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback